CDKN2A and neoplasm: Recently, plasma cfDNA profiling in 38 patients with advanced PC receiving first-line FOLFIRINOX chemotherapy could demonstrate that 65.8% of patients had at least one common driver gene alteration in KRAS, TP53, SMAD4, or CDKN2A in high concordance with corresponding tumor tissue (Table 2) (Wei et al. 2019).